Search clinical trials for: HIV Envelope Protein gp120

Total 34080 results

National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults

HIV Infections

United States
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults (HVTN 097)

HIV Infection

South Africa
GlaxoSmithKline
University Ghent

Completed

Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)

HIV Infections | Infection, Human Immunodeficiency Virus

Belgium
National Institute of Allergy and Infectious Diseases...

Completed

A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells

HIV Infections

United States
Hospitales Universitarios Virgen del Rocío
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Unknown

Vedolizumab Treatment in HIV-Infected Subjects Without Previous Antiretroviral Therapy

HIV Infections

Spain
Samaritan Pharmaceuticals, Inc

Completed

A Dose Response and Safety Study of Procaine HCl in HIV-Infected Patients

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
GlaxoSmithKline; Sanofi Pasteur, a Sanofi Company; HIV Vaccine Trials Network

Completed

Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine (HVTN107)

HIV Infections

South Africa, Mozambique, Zimbabwe
National Institute of Allergy and Infectious Diseases...
GlaxoSmithKline; Sanofi Pasteur, a Sanofi Company

Completed

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants (HVTN 120)

HIV Infections

United States, Zimbabwe, Tanzania, Zambia
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID)

Active, not recruiting

Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants (HVTN 135)

HIV Infections

South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

HIV Infections

United States, South Africa
Marcus Altfeld, M.D., Ph.D.
GlaxoSmithKline

Completed

Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
GlaxoSmithKline; Bill and Melinda Gates Foundation; Medical Research Council; Sanofi... and other collaborators

Completed

A Safety and Immune Response Study of 2 Experimental HIV Vaccines

HIV Infection

South Africa
National Institute of Allergy and Infectious Diseases...
University of Maryland, Baltimore; Duke University; HIV Vaccine Trials Network... and other collaborators

Withdrawn

Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants

HIV Infections
National Institute of Allergy and Infectious Diseases...
Sanofi; GlaxoSmithKline; Bill and Melinda Gates Foundation

Completed

Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (HVTN702)

HIV Infections

South Africa
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaborators

Active, not recruiting

Evaluating the Safety and Immunogenicity of HIV-1 Vaccines Based on Chimpanzee Serotypes of Ad Expressing Clade C gp140 and a CH505TF gp120 Protein Boost in Healthy, HIV- Uninfected Adult Participants (HVTN139)

HIV Infections

South Africa
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.; MicroGeneSys Inc (nka Protein Sciences Corporation)

Completed

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Biocine

Completed

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months

HIV Infections

United States
United Biomedical

Completed

A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.

Completed

A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.

Completed

A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Biocine

Completed

Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.; Biocine

Completed

A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.; Biocine

Completed

A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers

HIV Infections | HIV Seronegativity

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Pasteur Merieux Connaught

Completed

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
Worcester HIV Vaccine
Brigham and Women's Hospital; Access to Advanced Health Institute (AAHI)

Completed

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Novartis Vaccines; HIV Vaccine Trials Network; IPPOX Foundation

Completed

Safety and Immune Response to a Clade C DNA HIV Vaccine (HVTN111)

HIV Infections

South Africa, Zambia, Tanzania
National Institute of Allergy and Infectious Diseases...

Completed

Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)

HIV Infections | Pregnancy

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.; Glaxo Wellcome

Completed

A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3

HIV Infections

United States
Henry M. Jackson Foundation for the Advancement...
US Military HIV Research Program; Janssen Vaccines & Prevention B.V.

Not yet recruiting

Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission (RV582)

HIV-1-infection

Thailand
National Institute of Allergy and Infectious Diseases...

Withdrawn

Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)

HIV Infections | Pregnancy | HIV Seronegativity
National Institute of Allergy and Infectious Diseases...
Biocine

Completed

A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus

HIV Infections | Systemic Lupus Erythematosus

United States
University of Maryland, Baltimore
Bill and Melinda Gates Foundation; Auro Vaccines LLC

Completed

A Safety and Immunogenicity Trial of IHV01 (FLSC-001)

HIV Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers

HIV Infections | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

HIV Infections

United States
VaxGen

Completed

Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand

HIV Infections | HIV Seronegativity

Thailand

3

Subscribe